Ofatumumab-associated acute respiratory manifestations: clinical characteristics and treatment

Br J Clin Pharmacol. 2016 Oct;82(4):1146-8. doi: 10.1111/bcp.13029. Epub 2016 Jun 28.

Authors

Alice Bonanni¹, Enrica Bertelli¹, Andrea Moscatelli², Elisabetta Lampugnani², Monica Bodria¹, Pietro Ravani³, Gian Marco Ghiggeri⁴

Affiliations

¹ Division of Nephrology, Dialysis, Transplantation, Giannina Gaslini Children's Hospital, Genoa, 16148, Italy.
² Neonatal and Pediatric ICU, Dept. of Critical Care and Perinatal Medicine, Giannina Gaslini Children's Hospital, Genoa, 16148, Italy.
³ Division of Nephrology, University of Calgary, Calgary, Alberta, T2N 2T9, Canada.
⁴ Division of Nephrology, Dialysis, Transplantation, Giannina Gaslini Children's Hospital, Genoa, 16148, Italy. [email protected].

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Albuterol / therapeutic use
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Bronchodilator Agents / therapeutic use
Child
Child, Preschool
Female
Humans
Male
Nephrotic Syndrome / drug therapy
Respiratory Tract Diseases / chemically induced*
Respiratory Tract Diseases / prevention & control

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Bronchodilator Agents
ofatumumab
Albuterol